Is GHK-Cu FDA Approved?

No. GHK-Cu is not an FDA-approved drug for any indication. It has no approved application in Drugs@FDA under any of its recognized names, and it is not on the 503A bulk drug substances list. Its actual position is narrower and more specific than "unapproved," and most pages describing it get the detail wrong in one direction or the other. The precise record is below, verified against FDA primary sources on July 16, 2026.

Author: Nox Amino Research Team Reviewed by: the Nox Amino Research Team Published: July 16, 2026 · Updated: July 16, 2026 Editorial methodology: /learn/editorial-standards

Research Use Only (RUO). Materials referenced on this page are intended exclusively for laboratory research and analytical use. They are not drugs, cosmetics, dietary supplements, or articles for human or veterinary consumption, and nothing here is medical advice, a cosmetic claim, or a recommendation for use in or on the body. This page describes regulatory records only and deliberately contains no efficacy claims and no guidance for any use.

Why the name matters first

Searches for this question often fail because FDA does not primarily file the molecule under "GHK-Cu." FDA's substance registry gives the preferred substance name PREZATIDE COPPER, UNII 6BJQ43T1I9, CAS 89030-95-5, with synonyms including Copper Tripeptide-1 and GHK Copper. Checking only "GHK-Cu" and concluding "no record found" is how inaccurate answers get published.

Searching Drugs@FDA across all of those names returns no approved NDA, ANDA, or BLA. The answer to the headline question is therefore no, under every name FDA recognizes.

The 503A bulks list: not on it, and "Category 1" is not approval

The codified 503A bulk drug substances list at 21 CFR 216.23(a) contains exactly six substances: Brilliant Blue G, Cantharidin, Diphenylcyclopropenone, N-acetyl-D-glucosamine, Squaric acid dibutyl ester, and Thymol iodide. GHK-Cu is not among them.

FDA's nominations document (updated May 14, 2026) states that "GHK-Cu (except for injectable routes of administration) will be added back to category 1" (FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A). Category 1 means under evaluation, not approved and not listed. The same document records that FDA "intends to consult the Pharmacy Compounding Advisory Committee (PCAC) before the end of February 2027" on potential inclusion.

Category 2: what actually happened, and the tense that matters

This is the detail most vendor pages state incorrectly, in both directions.

GHK-Cu for injectable routes of administration was added to 503A Category 2 on September 29, 2023. Category 2 covers bulk substances raising significant safety concerns. FDA's stated concern, in its own words, was that "compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity" (FDA, Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks).

Those nominations were subsequently withdrawn by the nominators. On FDA's current page, GHK-Cu for injectable routes appears in the nominated-but-withdrawn subsection rather than in the active Category 2 table. The active Category 2 table today lists: Cesium chloride, Chloral hydrate, Diethylstilbestrol, Domperidone, Edetate disodium (except ophthalmic), Germanium sesquioxide, GHRP-2, GHRP-6, Ibutamoren mesylate, Ipamorelin acetate, Kisspeptin-10, Neomycin sulfate, Quinacrine hydrochloride, and Tranilast.

So both of these common statements are wrong:

Common claim	Status	Accurate version
"GHK-Cu is on FDA's Category 2 safety-risk list"	Inaccurate (tense)	It was added for injectable routes on 2023-09-29; the nominations were later withdrawn and it now sits in the withdrawn subsection
"GHK-Cu was never named by FDA"	Inaccurate	It was named, specifically for injectable routes, with immunogenicity cited
"GHK-Cu is FDA approved"	Inaccurate	No approved application exists under any FDA-recognized name
"It has an NDC, so FDA cleared it"	Inaccurate	FDA: "Assignment of an NDC number does not in any way denote FDA approval of the product"

This record has moved twice during 2026 and has a PCAC consultation pending, so it is a page we date-stamp and revisit rather than treat as settled. Verified July 16, 2026.

Why "it's in skincare" is not approval

Copper tripeptide-1 appears widely in cosmetic ingredient lists, which leads to a reasonable but incorrect inference.

Copper Tripeptide-1 is an INCI name, an industry-dictionary labeling convention that FDA's cosmetic labeling rule references at 21 CFR 701.3(c)(2). It is a naming standard, not an evaluation. FDA is explicit that "cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives" (FDA, FDA Authority Over Cosmetics).

The drug and cosmetic definitions differ by intent, not by molecule. FDA defines a drug at FD&C Act 201(g)(1) as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease", and a cosmetic at 201(i) as an article for "cleansing, beautifying, promoting attractiveness, or altering the appearance" (FDA, Is It a Cosmetic, a Drug, or Both?). One ingredient can therefore land in different categories depending entirely on what the seller intends it for.

One further nuance, because a careless reader will find it and misread it: a single listed OTC monograph product contains prezatide copper as an active ingredient. The OTC monograph pathway is not approval, and FDA says so directly: "Assignment of an NDC number does not in any way denote FDA approval of the product" (FDA, National Drug Code Directory).

What "research use only" does and does not mean

Because this question is usually asked alongside "so can I buy it," the honest regulatory answer belongs here too.

Research use only is not an FDA safe harbor. RUO is a defined labeling concept for in vitro diagnostic products under 21 CFR 809.10(c). There is no FDA-recognized research-use-only exemption for a peptide sold as a chemical.

What governs instead is intended use. Under 21 CFR 201.128, "the intent may be shown by such persons' expressions, the design or composition of the article." FDA applies this to peptide sellers explicitly and has stated in writing that a disclaimer does not cure it: "Despite statements on your product labeling and website such as 'research use only'... evidence obtained from your website establishes that certain products offered for sale... are drugs intended for human use" (FDA Warning Letter, USApeptide.com, February 26, 2025).

GHK-Cu has also been named in an FDA enforcement action against a compounder, which listed products "compounded... using Follistatin, GHRP-2, GHRP-6... Epitalon, GHK-Cu, IGF1-LR3" (FDA Warning Letter, Tailor Made Compounding LLC, April 1, 2020).

The practical takeaway for laboratory sourcing is that a compound's status is a matter of records and intent, not marketing language. That is why Nox Amino describes stocked materials by analytical attributes only: identity and purity, documented per lot.

What this means for selecting a reference material

Regulatory status answers "what is this in the eyes of FDA." It does not answer "is this vial what the label says," which is a separate and analytical question. Identity and purity are documented on a batch-specific Certificate of Analysis, typically using mass spectrometry for identity and HPLC for purity. Our walkthrough is at how to read a peptide COA.

For the published research literature on this molecule, which this page deliberately does not cover, see GHK-Cu: what the copper-peptide research shows. To view COA-verified GHK-Cu, see /shop/ghk-cu or the batch report at /coas/NoxR2602190085.

Create a free account to access batch-specific analytical data and member pricing. → Create your account

This article cites FDA primary records and registry entries for informational and laboratory-research purposes only, and is accurate as of the verification date stated above; FDA records change. It is not legal or regulatory advice. Nox Amino sells research compounds intended for laboratory and analytical use only, not for human or animal consumption. Nothing on this page is medical advice or a cosmetic claim. Editorial methodology: /learn/editorial-standards.

Frequently Asked Questions

Is GHK-Cu FDA approved?

No. GHK-Cu is not an FDA-approved drug for any indication. A search of Drugs@FDA under each of its FDA-recognized names, including prezatide copper (the preferred substance name, UNII 6BJQ43T1I9) and copper tripeptide-1, returns no approved application. It also does not appear on the 503A bulk drug substances list codified at 21 CFR 216.23, which contains only six substances. As stocked by Nox Amino, GHK-Cu is a reference material for laboratory research use only.

Is GHK-Cu on FDA's Category 2 safety-risk list?

Not currently, but it was. FDA added GHK-Cu for injectable routes of administration to 503A Category 2 on September 29, 2023, citing that compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity. Those nominations were later withdrawn by the nominators, so GHK-Cu for injectable routes now appears in FDA's nominated-but-withdrawn list rather than the active Category 2 table. Both the claim that it is currently on the Category 2 list and the claim that it was never named are inaccurate. Verified against FDA records as of July 16, 2026.

Does copper tripeptide-1 being in cosmetics mean FDA approved it?

No. Copper Tripeptide-1 is an INCI name, an industry-dictionary labeling convention referenced by FDA's cosmetic labeling rule at 21 CFR 701.3(c)(2). It is a naming standard, not an approval. FDA states that cosmetic products and ingredients do not need FDA premarket approval, with the exception of color additives. Appearing in a cosmetic ingredient list therefore carries no FDA endorsement and does not transfer to any other product category.

What is GHK-Cu's status on the 503A bulks list?

It is not on the list. The codified 503A bulks list at 21 CFR 216.23(a) contains six substances: Brilliant Blue G, Cantharidin, Diphenylcyclopropenone, N-acetyl-D-glucosamine, Squaric acid dibutyl ester, and Thymol iodide. GHK-Cu is absent. FDA's nominations document, updated May 14, 2026, states that GHK-Cu (except for injectable routes of administration) will be added back to category 1, which means under evaluation, not approved. FDA has stated it intends to consult the Pharmacy Compounding Advisory Committee before the end of February 2027.

Does a research-use-only label exempt a peptide from FDA rules?

No, and this is widely misunderstood. Research use only is a defined labeling concept for in vitro diagnostic products under 21 CFR 809.10(c), not a recognized exemption for a peptide sold as a chemical. Under 21 CFR 201.128, FDA determines intended use from the seller's total marketing context, stating the intent may be shown by such persons' expressions, the design or composition of the article. FDA has told peptide sellers in writing that research-use-only statements do not override that determination.